| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ISOX | CTRPv2 | pan-cancer | AAC | -0.0053 | 0.9 |
| mRNA | navitoclax:piperlongumine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.006 | 0.9 |
| mRNA | Sorafenib | FIMM | pan-cancer | AAC | -0.027 | 0.9 |
| mRNA | XMD8-85 | GDSC1000 | pan-cancer | AAC | 0.0085 | 0.9 |
| mRNA | LY317615 | GDSC1000 | pan-cancer | AAC | 0.0057 | 0.9 |
| mRNA | JW-74 | CTRPv2 | pan-cancer | AAC | -0.0073 | 0.9 |
| mRNA | Cytarabine | FIMM | pan-cancer | AAC | 0.024 | 0.9 |
| mRNA | BRD-K34099515 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.9 |
| mRNA | KU-55933 | CTRPv2 | pan-cancer | AAC | 0.0055 | 0.9 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | 0.0046 | 0.9 |